TGFB1 and non-small cell lung carcinoma: By inhibiting Smad and non-Smad signaling, cilengitide enhanced the effect of gefitinib on NSCLC cell death and TGF-β–induced EMT phenotype change without severe cytotoxicity in normal cells [36].